Review HBV drug resistance: Mechanisms, detection and interpretation

[1]  M. Levrero,et al.  116 A multicenter italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2-year analysis of 650 patients , 2006 .

[2]  M. Colombo,et al.  85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma , 2006 .

[3]  Yun Sun,et al.  Dual-probe assay for detection of lamivudine-resistance hepatitis B virus by real-time PCR. , 2006, Journal of virological methods.

[4]  S. Locarnini,et al.  Cellular and virological mechanisms of HBV drug resistance. , 2006, Journal of hepatology.

[5]  J. Gollan,et al.  Emerging therapeutics for chronic hepatitis B. , 2006, Annual review of medicine.

[6]  B. Hansen,et al.  Relapse in HBeAg-positive chronic hepatitis B after Peg-Interferon alpha-2b therapy alone or in combination with lamivudine , 2006 .

[7]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. , 2006, Journal of hepatology.

[8]  F. Zoulim.  Assessment of treatment efficacy in HBV infection and disease. , 2006, Journal of hepatology.

[9]  C. Thio.  Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer? , 2006, Journal of hepatology.

[10]  A. Craxì,et al.  Treatment options in HBV. , 2006, Journal of hepatology.

[11]  M. Goto,et al.  Detection of Point Mutations in the HBV Polymerase Gene Using a Fluorescence Intercalator in Reverse Micelles , 2008, Biotechnology progress.

[12]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[13]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[14]  Chang-jie Chen,et al.  Rapid and Accurate Genotyping of YMDD Motif Variants in the Hepatitis B Virus Genome by an Improved Reverse Dot Blot Method , 2005, Journal of Clinical Microbiology.

[15]  Y. Geng,et al.  Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance. , 2005, Pharmacogenomics.

[16]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[17]  J. Germer,et al.  Evaluation of the MagNA Pure LC used with the TRUGENE HBV Genotyping Kit. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[18]  C. Thio,et al.  Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Eva Herrmann,et al.  Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. , 2005, Journal of hepatology.

[20]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[21]  N. Enomoto,et al.  Polymerase Domain B Mutation Is Associated with Hepatitis Relapse during Long-Term Lamivudine Therapy for Chronic Hepatitis B , 2005, Intervirology.

[22]  E. Palumbo,et al.  Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B. , 2005, The new microbiologica.

[23]  C. Yurdaydın,et al.  Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy , 2005, Antimicrobial Agents and Chemotherapy.

[24]  Huiling Yang,et al.  Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV , 2005, Antiviral therapy.

[25]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[26]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[27]  Mehmet Ozsoz,et al.  Label-free electrochemical hybridization genosensor for the detection of hepatitis B virus genotype on the development of Lamivudine resistance. , 2005, Analytical chemistry.

[28]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[29]  B. Spiegel,et al.  Treatment Alternatives for Chronic Hepatitis B Virus Infection: A Cost-Effectiveness Analysis , 2005, Annals of Internal Medicine.

[30]  F. Zoulim.  Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. , 2005, The Journal of antimicrobial chemotherapy.

[31]  F. Azorin,et al.  Adefovir Dipivoxil Therapy in Liver Transplant Recipients With Lamivudine-Resistant Hepatitis B Virus , 2005 .

[32]  S. Ahn,et al.  Evaluation of Methods for Monitoring Drug Resistance in Chronic Hepatitis B Patients during Lamivudine Therapy Based on Mass Spectrometry and Reverse Hybridization , 2005, Antiviral therapy.

[33]  A. Mazuecos,et al.  Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. , 2005, Transplantation proceedings.

[34]  Z. Li,et al.  Quantification of the relative levels of wild‐type and lamivudine‐resistant mutant virus in serum of HBV‐infected patients using microarray , 2005, Journal of viral hepatitis.

[35]  G. Portella,et al.  Three‐phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B , 2005, Journal of viral hepatitis.

[36]  R. D. de Man,et al.  Quantification of the newly detected lamivudine resistant YSDD variants of Hepatitis B virus using molecular beacons. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[37]  M. Chevallier,et al.  Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure. , 2005, Journal of hepatology.

[38]  Erwin Sablon,et al.  Advances in Molecular Diagnosis of HBV Infection and Drug Resistance , 2005, International journal of medical sciences.

[39]  M. Wulfsohn,et al.  Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients , 2005, Journal of viral hepatitis.

[40]  M. Colombo,et al.  Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma , 2005 .

[41]  R. Stauber,et al.  Drugs in development for hepatitis B. , 2005 .

[42]  R. Gish.  Clinical trial results of new therapies for HBV: implications for treatment guidelines. , 2005, Seminars in liver disease.

[43]  A. Antinori,et al.  Selection of Antiretroviral Therapy Guided by Genotypic or Phenotypic Resistance Testing: An Open-Label, Randomized, Multicenter Study (PhenGen) , 2004, Journal of acquired immune deficiency syndromes.

[44]  M. Yuen,et al.  Adefovir dipivoxil in chronic hepatitis B infection , 2004, Expert opinion on pharmacotherapy.

[45]  S. Locarnini,et al.  Entecavir for the treatment of chronic hepatitis B , 2004, Expert review of anti-infective therapy.

[46]  F. Zoulim,et al.  A new strategy for studying In Vitro the drug susceptibility of clinical isolates of human hepatitis B virus , 2004, Hepatology.

[47]  V. Soriano,et al.  Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. , 2004, Journal of virological methods.

[48]  J. Odeberg,et al.  Pyrosequencing for Detection of Lamivudine-Resistant Hepatitis B Virus , 2004, Journal of Clinical Microbiology.

[49]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[50]  J. Heo,et al.  Oligonucleotide Chip for Detection of Lamivudine-Resistant Hepatitis B Virus , 2004, Journal of Clinical Microbiology.

[51]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[52]  M. Brunetto,et al.  Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. , 2004, Current pharmaceutical design.

[53]  P. Cane,et al.  Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. , 2004, Journal of hepatology.

[54]  N. Kim,et al.  Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. , 2004, Journal of hepatology.

[55]  Yongwook Choi,et al.  Increased DNA polymerase fidelity of the Lamivudine resistant variants of human hepatitis B virus DNA polymerase. , 2004, Journal of biochemistry and molecular biology.

[56]  R. Chung,et al.  Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[57]  B. Tehan,et al.  Comparisons of the Hbv and HIV Polymerase, and Antiviral Resistance Mutations , 2003, Antiviral therapy.

[58]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[59]  V. Leb,et al.  Fully Automated, Internally Controlled Quantification of Hepatitis B Virus DNA by Real-Time PCR by Use of the MagNA Pure LC and LightCycler Instruments , 2004, Journal of Clinical Microbiology.

[60]  C. Katlama,et al.  In Vitro Susceptibility of Lamivudine-Resistant Hepatitis B Virus to Adefovir and Tenofovir , 2003, Antiviral therapy.

[61]  Huiling Yang,et al.  In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. , 2004, Antiviral research.

[62]  S. Locarnini,et al.  Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? , 2004, Gastroenterology.

[63]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[64]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[65]  M. Otto,et al.  Mechanism of Antiviral Activities of 3′-Substituted L-Nucleosides against 3Tc-Resistant HBV Polymerase: A Molecular Modelling Approach , 2003, Antiviral chemistry & chemotherapy.

[66]  C. Osiowy,et al.  Evaluation of the INNO-LiPA HBV Genotyping Assay for Determination of Hepatitis B Virus Genotype , 2003, Journal of Clinical Microbiology.

[67]  Michael D. Miller,et al.  The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro , 2003, Journal of Virology.

[68]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[69]  C. Gibbs,et al.  Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil , 2003 .

[70]  K. Walters,et al.  Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening , 2003, Antimicrobial Agents and Chemotherapy.

[71]  H. Isom,et al.  Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine‐resistant HBV in vitro , 2003, Hepatology.

[72]  W. Delaney,et al.  Phenylpropenamide Derivatives AT-61 and AT-130 Inhibit Replication of Wild-Type and Lamivudine-Resistant Strains of Hepatitis B Virus In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[73]  M. Manns,et al.  In Vitro Susceptibilities of Wild-Type or Drug-Resistant Hepatitis B Virus to (−)-β-d-2,6-Diaminopurine Dioxolane and 2′-Fluoro-5-Methyl-β-l-Arabinofuranosyluracil , 2001, Antimicrobial Agents and Chemotherapy.

[74]  M. Manns,et al.  Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus , 2001, Antimicrobial Agents and Chemotherapy.

[75]  S. Sarafianos,et al.  Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.

[76]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[77]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[78]  L. Fu,et al.  Characterization of Novel Human Hepatoma Cell Lines with Stable Hepatitis B Virus Secretion for Evaluating New Compounds against Lamivudine- and Penciclovir-Resistant Virus , 2000, Antimicrobial Agents and Chemotherapy.

[79]  D. Richman.  The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B , 2000, Hepatology.

[80]  C. Chu,et al.  Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.

[81]  Nicholson,et al.  Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L‐FMAU, DAPD, penciclovir and lobucavir , 2000, Journal of viral hepatitis.

[82]  C. Katlama,et al.  Long‐term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus–infected patients , 1999, Hepatology.

[83]  H. Asakura,et al.  Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B , 1999, Journal of medical virology.

[84]  H. Isom,et al.  Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus , 1998, Hepatology.

[85]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .

[86]  Y. Cheng,et al.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.

[87]  J. Wands,et al.  Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective , 1998, Hepatology.

[88]  P. Angus,et al.  Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. , 1997, Journal of hepatology.

[89]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.